Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. - Wikidata - wikimedia - TriplyDB

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.

http://www.wikidata.org/entity/Q43660475

about

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance Thrombosis in multiple myeloma Update on therapeutic options in Waldenström macroglobulinemia Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation Management of multiple myeloma with bortezomib: experts review the data and debate the issues.Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma Thalidomide-associated thrombocytopenia.Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study Access to thalidomide for the treatment of multiple myeloma in Canada: physician behaviours and ethical implications.Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.Management of thalidomide toxicity.Thalidomide as an anti-cancer agent.Thalidomide for the treatment of relapsed and refractory multiple myeloma.Thalidomide in multiple myeloma--from the clinic to the laboratory.Thalidomide dosing in patients with relapsed or refractory multiple myeloma.The use of novel agents in the treatment of relapsed and refractory multiple myeloma Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.Thalidomide and its derivatives: new promise for multiple myeloma.Treatment advances in multiple myeloma.Stem cell transplantation for multiple myeloma.Molecular biological design of novel antineoplastic therapies.Epidemiology and pathophysiology of cancer-associated thrombosis.Thalidomide for the treatment of multiple myeloma.Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma.Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.Thalidomide and immunomodulatory drugs in the treatment of cancer.Thalidomide: present and future in multiple myeloma.Dyspnea during thalidomide treatment for advanced ovarian cancer.Targeted therapy in multiple myeloma.Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues.Current treatment options for myeloma.

P2860

Q27004421-8E0B69B2-DB4A-4ADB-A63A-641BFC761B98 Q27008491-853A722E-C3C2-4A49-BA69-17E70B0B4DAE Q28219961-47BA3AF4-EE2E-4A5A-BFA9-A25859C6CA00 Q28304195-46544A24-DE65-471D-8EC2-4DBDF4D75D0C Q28478937-3D41E0E5-E2D0-416B-ABB8-BCDC724D9D8D Q31098282-54285328-839D-4F1E-80BE-F6596D0FCC0C Q33289791-CDB6A276-66C0-448C-9747-432CC603F1B6 Q33364235-0FC673C9-1C7E-4D80-97A3-7D6DE7DBD7E3 Q33367833-1520A7BC-6C5C-4300-B0C4-ADED6453361B Q33368888-E3101098-1A9F-42AE-8A9B-C3FF5723126E Q33389075-E524CDFF-24F6-437D-87B0-044418AF0215 Q33426534-6EF3C997-0BBA-44A8-9485-52E99FB3722A Q33702365-064ABA72-EC90-4678-87CE-785617B01F71 Q33874179-E0ED7ABB-3BCF-4D8A-BBC9-C285366A67F4 Q33931754-04036384-2893-428D-AD6D-0248411DC516 Q34035424-A48E94E4-DE6F-4CBA-999B-73B05F2BAC0C Q34122646-1522487E-DED4-4A2C-A085-053CDDBB3DD6 Q34335445-5F2BEDDB-884E-4A28-BE16-EB26DDA9C0B9 Q34343991-BE834906-A2C1-4A36-911C-EEDC8E3089EE Q34778074-3F129F14-E571-477B-8AC0-19FB8EE61B2C Q34782279-02F82B76-1F55-4072-A869-35FA4D4F5F97 Q35008319-F0DAABEE-B362-47E5-A2DE-AC140E7D63EB Q35092960-1E144BAA-9D6B-43A7-9CC6-E6D5F66A42DE Q35097319-1E8E4E06-B805-44EC-B565-778AE88E9D8A Q35175287-69C5A768-54D3-4F53-876E-A6E5FC502167 Q35198927-9A66A49D-B42D-429C-970F-1811CC461EE1 Q35569462-8640F4A9-F878-4B56-8641-5FCE79055C98 Q35688848-0271AD46-D174-497D-8275-F0A3764AAD8D Q35692626-063DAA1B-C05A-4085-82D5-95123F4EE00B Q35790781-94E3E6BD-7EBF-4518-9ACF-B3D2F3E2EB36 Q35860789-841B2E7A-679B-454C-9267-CF792B2607C4 Q35870500-52087AB3-93C1-4438-8D9D-72921BC04E1D Q35904262-C4F6C6BC-497D-4095-894B-A9EE3824E17C Q35930659-8C7C6C04-5607-44D1-9754-435B9D60B2AC Q36040871-E4576973-8CC4-48C2-9986-B0FF1330D128 Q36066131-CF4BF858-38A2-4162-8010-9A1E67907370 Q36089929-7E8A3AA6-6047-4724-B34E-4A2AEE5D43D9 Q36108614-B211C5AF-0A65-4FC4-9CCD-F9DFFF2256FE Q36132803-2B17290B-51E0-4C40-AE48-C1E6EC06610B Q36163971-21EA7FF6-ACA5-41EF-86FA-360F9F6170B3

P2860

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.

http://www.wikidata.org/entity/Q43660475

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Extended survival in advanced ...... phase 2 study of 169 patients.

@en

Extended survival in advanced ...... phase 2 study of 169 patients.

@nl

type

label

Extended survival in advanced ...... phase 2 study of 169 patients.

@en

Extended survival in advanced ...... phase 2 study of 169 patients.

@nl

prefLabel

Extended survival in advanced ...... phase 2 study of 169 patients.

@en

Extended survival in advanced ...... phase 2 study of 169 patients.

@nl

P1433

Q43660475-2E73C285-6D20-4BDC-9A1D-FB64D0546825

P1476

Q43660475-7717A4F9-283B-47B4-8DD5-6AD275C38245

P2093

Q43660475-17636990-167D-4827-AA3D-8102678DD390

Q43660475-27C5F2A0-16A4-401B-AA5D-2527850CD2B8

Q43660475-3B6DCA6B-6BAC-4A23-BDFD-CCD5338E7AB0

Q43660475-46D5A172-AB28-4ED8-A7B4-66E4D3FE54E1

Q43660475-49ACD6F9-6096-4BC0-AD7F-C23F33001CE9

Q43660475-4FA90402-359C-4C3C-A504-9405086241E3

Q43660475-645E25BE-721C-4858-A9ED-5EA9B9E3C575

Q43660475-7226C491-7144-4908-B807-25887FDC246D

Q43660475-84E1CFC5-32C4-4F63-BB9A-DB4FDA306F0A

Q43660475-94B1B3FB-58DC-468D-A001-1E8611A0E5CD

P304

Q43660475-F7B42AB7-599D-4C40-B8A1-E853663C92A4

P31

Q43660475-B4BF7DA7-867F-4D3C-8FF0-EC86BDFA4FBE

P356

Q43660475-54F99779-A0B3-4C1F-978C-95A71B0B566D

P407

Q43660475-E63B9509-8619-414F-A3CC-3A0809764A73

P433

Q43660475-7ACD1CD1-E677-48A3-80BB-022192B4D981

P478

Q43660475-AE598656-9918-4600-9C91-3CF3CC98ACD2

P577

Q43660475-0E9FD787-FA93-49DB-A8BD-E4D174828273

P5875

Q43660475-0A076106-B980-4DE7-BBF1-9E3F63B3FF0D

P698

Q43660475-A91EAE66-3FCA-49D0-BDDB-0D690B036745

P921

Q43660475-5D42A8D9-2770-4579-B6E8-62C905638328

P356

BLOOD.V98.2.492

P1433

P1476

Extended survival in advanced ...... phase 2 study of 169 patients.

@en

P2093

Anaissie E

http://www.w3.org/2001/XMLSchema#string

Ayers D

http://www.w3.org/2001/XMLSchema#string

Badros A

http://www.w3.org/2001/XMLSchema#string

Barlogie B

http://www.w3.org/2001/XMLSchema#string

Desikan R

http://www.w3.org/2001/XMLSchema#string

Eddlemon P

http://www.w3.org/2001/XMLSchema#string

Epstein J

http://www.w3.org/2001/XMLSchema#string

Munshi N

http://www.w3.org/2001/XMLSchema#string

Shaughnessy J

http://www.w3.org/2001/XMLSchema#string

Spencer T

http://www.w3.org/2001/XMLSchema#string

P304

492-494

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD.V98.2.492

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2001-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11906267

http://www.w3.org/2001/XMLSchema#string

P698

11435324

http://www.w3.org/2001/XMLSchema#string

P921